Ads
related to: stanford hiv drug resistance database- HIV Treatment FAQs
Find Answers To Frequently Asked
Questions About HIV And Medication.
- Download Patient Brochure
Find Resources With Important Info
About Treatment And Switching.
- Patient Assistance Info
Discover If You Are Eligible To
Save On An HIV-1 Treatment Option.
- Learn How Treatment Works
Visit The Patient Website To Learn
How An HIV-1 Treatment Works.
- HIV Real Patient Stories
Watch The Stories Of People Who
Share Their Treatment Experiences.
- Sign Up For More Info
Learn About An HIV Treatment Option
Sign Up To Receive Information.
- HIV Treatment FAQs
Search results
Results From The WOW.Com Content Network
HIV Drug Resistance Database, also known as Stanford HIV RT and Protease Sequence Database, is a database at Stanford University that tracks 93 common mutations of HIV.It has been recompiled in 2008 listing 93 common mutations, after its initial mutation compilation in 2007 of 80 mutations.
The Stanford HIV RT and Protease Sequence Database (also called the “HIV Drug Resistance Database”) was formed in 1998 with HIV reverse transcriptase and protease sequences from persons with well-characterized antiretroviral treatment histories, and is publicly available to query resistance mutations and genotype-treatment, genotype ...
The Stanford HIV Drug Resistance Database and the International AIDS Society publish lists of the most important of these; first year listing 80 common mutations, and the latest year 93 common mutations, and made available through the Stanford HIV RT and Protease Sequence Database. [citation needed]
As of July 2017, the WHO is implementing the Global Action Plan on HIV drug resistance 2017–2021. It is a 5-year initiative intended to help countries around the world manage HIV drug resistance. [19] Among treatment methods, the World Health Organization acknowledges the importance of successful first-line treatments. [18]
A small proportion of humans show partial or apparently complete innate resistance to HIV, the virus that causes AIDS. [1] The main mechanism is a mutation of the gene encoding CCR5, which acts as a co-receptor for HIV. It is estimated that the proportion of people with some form of resistance to HIV is under 10%. [2]
Resistance ranged from 3.9% to 8.6% and reached 19.6% among people who have received and transitioned to a dolutegravir-containing antiretroviral therapy (ART) regimen to combat high HIV viral loads.
Ad
related to: stanford hiv drug resistance database